Hub : Traits :

Medication for pain relief, constipation, heartburn

269 significantly associated models · 40 unique genes.

Significant Loci

#	chr	p0	p1	# assoc genes	# joint genes	best TWAS P	best SNP P	cond SNP P	% var exp	joint genes
1	1	149771890	151174772	1	1	2.7e-07	2.5e-07	1.0000	100	TARS2
2	1	155739430	157168420	1	1	3.6e-10	6.4e-12	0.0044	83	MEF2D
3	1	173103273	175689679	4	1	9.1e-09	1.1e-09	1.0000	100	RABGAP1L
4	1	242590540	244359621	2	1	4.5e-08	3.1e-08	1.0000	100	SDCCAG8
5	2	26624843	28503968	5	2	4.0e-08	2.0e-07	0.8840	100	CGREF1 NRBP1
6	2	207244783	208729540	1	1	1.8e-07	1.3e-08	0.0122	80	KLF7
7	6	25285943	26689223	1	1	1.2e-13	4.7e-11	0.0112	85	U91328.21
8	6	34065982	35751895	2	2	1.2e-08	8.9e-09	0.2700	96	ANKS1A UHRF1BP1
9	6	96275538	97756290	3	1	4.1e-09	5.9e-10	0.0051	80	FHL5
10	12	56776586	58303535	4	3	2.1e-18	6.0e-18	1.0000	100	LRP1 TMEM194A
11	12	123502044	124005129	1	1	1.7e-07	1.0e-06	0.9200	100	CDK2AP1
12	15	80743350	81292020	1	1	4.8e-09	6.0e-09	1.0000	100	FAM108C1
13	17	42774693	43913030	9	1	1.6e-10	2.5e-09	0.2220	96	LRRC37A4P
14	17	44788310	45285474	2	1	1.4e-07	3.7e-07	1.0000	100	LRRC37A2

Pleiotropic Associations

Trait	chisq ratio	# genes⁺	# genes⁺⁺	% genes⁺⁺	corr	corr P	genes
Headache pain in last month	19.03	10	7	15.6	-0.96	4.3e-06	FHL5 LRP1 LRRC37A2 LRRC37A4P MEF2D RABGAP1L SDCCAG8 TARS2 TMEM194A U91328.21
Medication: Paracetamol	16.36	12	7	15.6	-0.98	6.3e-09	CGREF1 FAM108C1 FHL5 LRP1 LRRC37A2 LRRC37A4P MEF2D NRBP1 RABGAP1L SDCCAG8 TMEM194A U91328.21
Medication: Paracetamol	13.58	9	4	8.9	-0.98	2.0e-06	CGREF1 FHL5 LRP1 LRRC37A2 LRRC37A4P RABGAP1L SDCCAG8 TARS2 U91328.21
Medication: Ibuprofen (e.g. Nurofen)	10.72	7	1	2.2	-0.99	2.5e-06	FHL5 LRP1 LRRC37A2 MEF2D TARS2 TMEM194A U91328.21
Migraine (self-reported)	10.45	4	3	6.7	-0.99	7.7e-03	FHL5 LRP1 MEF2D TMEM194A
Hair/balding pattern: Pattern 4	9.46	2	2	4.4	0.00	1.0e+00	LRRC37A2 LRRC37A4P
Medication: Ibuprofen	8.23	3	1	2.2	0.00	1.0e+00	LRP1 MEF2D TMEM194A
Number of treatments/medications taken	8.09	9	2	4.4	-0.99	6.0e-07	ANKS1A CGREF1 FAM108C1 LRP1 MEF2D NRBP1 RABGAP1L SDCCAG8 U91328.21
Pain experienced in last month	7.70	5	1	2.2	1.00	9.6e-05	ANKS1A FHL5 KLF7 LRP1 RABGAP1L
Depressed Affect (Nagel 2018)	6.38	4	2	4.4	-0.95	4.9e-02	LRRC37A2 LRRC37A4P RABGAP1L SDCCAG8
Hair/balding pattern: Pattern 3	6.18	2	2	4.4	0.00	1.0e+00	LRRC37A2 LRRC37A4P
Neuroticism	6.06	3	2	4.4	0.00	1.0e+00	LRRC37A2 LRRC37A4P RABGAP1L
Triglycerides	5.99	2	2	4.4	0.00	1.0e+00	CGREF1 NRBP1
Relative age of first facial hair	5.72	4	2	4.4	-0.67	3.3e-01	LRRC37A2 LRRC37A4P RABGAP1L TMEM194A
Neuroticism (Nagel 2018)	5.69	3	2	4.4	0.00	1.0e+00	LRRC37A2 LRRC37A4P RABGAP1L
Sensitivity / hurt feelings	5.47	2	2	4.4	0.00	1.0e+00	LRRC37A2 LRRC37A4P
Mood swings	5.35	2	2	4.4	0.00	1.0e+00	LRRC37A2 LRRC37A4P
Neuroticism score	5.30	3	2	4.4	0.00	1.0e+00	LRRC37A2 LRRC37A4P RABGAP1L
Vitamin and mineral supplements	5.21	2	2	4.4	0.00	1.0e+00	LRP1 TMEM194A
Forced expiratory volume in 1-second (FEV1)	5.16	4	3	6.7	0.42	5.8e-01	ANKS1A LRRC37A2 LRRC37A4P U91328.21
Alcohol intake frequency.	5.16	5	3	6.7	-0.94	1.7e-02	CDK2AP1 CGREF1 LRP1 LRRC37A2 LRRC37A4P
Blood Red Count	5.10	4	3	6.7	-0.86	1.4e-01	LRRC37A2 LRRC37A4P NRBP1 RABGAP1L
Forced vital capacity (FVC)	4.97	4	4	8.9	0.46	5.4e-01	ANKS1A LRRC37A2 LRRC37A4P U91328.21
Waist Hip Ratio (WHR)	4.95	5	5	11.1	-0.72	1.7e-01	CDK2AP1 LRRC37A2 LRRC37A4P MEF2D UHRF1BP1
Lung FVC	4.94	3	2	4.4	0.00	1.0e+00	LRRC37A2 LRRC37A4P MEF2D
Forced expiratory volume in 1-second (FEV1), predicted percentage	4.93	3	3	6.7	0.00	1.0e+00	LRRC37A2 LRRC37A4P U91328.21
Blood Platelet Count	4.83	9	6	13.3	-0.51	1.6e-01	CDK2AP1 CGREF1 KLF7 LRRC37A2 LRRC37A4P MEF2D NRBP1 TARS2 UHRF1BP1
Forced expiratory volume in 1-second (FEV1), Best measure	4.72	4	3	6.7	0.43	5.7e-01	ANKS1A LRRC37A2 LRRC37A4P U91328.21
Diastolic blood pressure, automated reading	4.60	5	4	8.9	-0.96	8.2e-03	CDK2AP1 FAM108C1 FHL5 SDCCAG8 U91328.21
Forced vital capacity (FVC), Best measure	4.59	4	3	6.7	0.49	5.1e-01	ANKS1A LRRC37A2 LRRC37A4P U91328.21
Ovarian Cancer	4.57	2	2	4.4	0.00	1.0e+00	LRRC37A2 LRRC37A4P
Sitting height	4.50	7	4	8.9	0.28	5.4e-01	CDK2AP1 CGREF1 FAM108C1 LRP1 LRRC37A2 LRRC37A4P UHRF1BP1
Miserableness	4.48	3	1	2.2	0.00	1.0e+00	LRRC37A2 LRRC37A4P SDCCAG8
Medication: Aspirin	4.46	2	0	0.0	0.00	1.0e+00	KLF7 MEF2D
Number of self-reported non-cancer illnesses	4.32	4	0	0.0	-1.00	1.2e-03	ANKS1A CGREF1 KLF7 UHRF1BP1
Relative age voice broke	4.20	2	2	4.4	0.00	1.0e+00	LRRC37A2 LRRC37A4P
BMI	4.15	7	3	6.7	-0.26	5.7e-01	ANKS1A FAM108C1 FHL5 LRP1 MEF2D RABGAP1L UHRF1BP1
Frequency of tenseness / restlessness in last 2 weeks	4.14	2	1	2.2	0.00	1.0e+00	LRRC37A2 LRRC37A4P
Fed-up feelings	4.13	3	2	4.4	0.00	1.0e+00	CDK2AP1 LRRC37A2 LRRC37A4P
Asthma (self-reported)	4.09	5	1	2.2	0.73	1.6e-01	CDK2AP1 LRP1 TARS2 TMEM194A U91328.21
Medication: Aspirin	4.07	2	0	0.0	0.00	1.0e+00	KLF7 MEF2D
Asthma	4.05	4	1	2.2	0.81	1.9e-01	LRP1 TARS2 TMEM194A U91328.21
Leg fat percentage (left)	3.98	3	2	4.4	0.00	1.0e+00	ANKS1A LRP1 UHRF1BP1
Leg fat percentage (right)	3.97	5	2	4.4	-0.50	3.9e-01	ANKS1A FHL5 LRP1 TARS2 UHRF1BP1
Leg fat mass (right)	3.88	3	2	4.4	0.00	1.0e+00	ANKS1A FAM108C1 UHRF1BP1
Medication: Blood pressure	3.84	3	0	0.0	0.00	1.0e+00	FAM108C1 LRRC37A2 LRRC37A4P
Blood Eosinophil Count	3.83	8	6	13.3	0.33	4.2e-01	ANKS1A CDK2AP1 KLF7 LRP1 LRRC37A2 LRRC37A4P TARS2 TMEM194A
Hip circumference	3.83	5	1	2.2	-0.41	4.9e-01	ANKS1A CDK2AP1 FAM108C1 RABGAP1L UHRF1BP1
Respiratory disease	3.81	5	2	4.4	0.43	4.7e-01	FHL5 LRP1 RABGAP1L TARS2 TMEM194A
Leg fat mass (left)	3.81	3	2	4.4	0.00	1.0e+00	ANKS1A FAM108C1 UHRF1BP1
Schizophrenia (2018)	3.76	2	1	2.2	0.00	1.0e+00	CDK2AP1 U91328.21
Mouth/teeth dental problems: Mouth ulcers	3.72	3	1	2.2	0.00	1.0e+00	LRRC37A2 LRRC37A4P SDCCAG8
Body fat percentage	3.69	3	2	4.4	0.00	1.0e+00	ANKS1A LRP1 UHRF1BP1
Knee pain experienced in last month	3.69	2	0	0.0	0.00	1.0e+00	RABGAP1L SDCCAG8
Trunk fat percentage	3.64	3	2	4.4	0.00	1.0e+00	ANKS1A LRRC37A2 UHRF1BP1
Average weekly champagne plus white wine intake	3.64	2	0	0.0	0.00	1.0e+00	LRRC37A2 LRRC37A4P
Hypertension (Self-reported)	3.62	4	2	4.4	-0.98	1.8e-02	CGREF1 FAM108C1 FHL5 SDCCAG8
Cardiovascular Disease	3.61	6	2	4.4	-0.97	1.2e-03	ANKS1A CGREF1 FAM108C1 FHL5 SDCCAG8 UHRF1BP1
Vascular/heart problems diagnosed by doctor	3.60	5	1	2.2	0.98	2.9e-03	CGREF1 FAM108C1 FHL5 MEF2D SDCCAG8
High blood pressure	3.57	4	1	2.2	-0.98	1.8e-02	CGREF1 FAM108C1 FHL5 SDCCAG8
Trunk fat mass	3.55	4	2	4.4	-0.63	3.7e-01	ANKS1A FAM108C1 LRRC37A2 UHRF1BP1
Medication: Omeprazole	3.55	2	0	0.0	0.00	1.0e+00	TARS2 UHRF1BP1
Peak expiratory flow (PEF)	3.54	4	2	4.4	0.44	5.6e-01	LRRC37A2 LRRC37A4P TARS2 U91328.21
Overall health rating	3.54	3	0	0.0	0.00	1.0e+00	KLF7 SDCCAG8 UHRF1BP1
High cholesterol (Self-reported)	3.53	1	1	2.2	0.00	1.0e+00	CGREF1
Whole body fat mass	3.50	3	2	4.4	0.00	1.0e+00	ANKS1A FAM108C1 UHRF1BP1
Neuroticism (2016)	3.49	2	0	0.0	0.00	1.0e+00	LRRC37A2 LRRC37A4P
Gout (self-reported)	3.46	1	1	2.2	0.00	1.0e+00	CGREF1
Fasting Glucose	3.43	1	1	2.2	0.00	1.0e+00	CGREF1
Medication for cholesterol	3.43	2	0	0.0	0.00	1.0e+00	CGREF1 FAM108C1
Body mass index (BMI)	3.39	3	2	4.4	0.00	1.0e+00	ANKS1A FAM108C1 UHRF1BP1
Worry (Nagel 2018)	3.30	3	2	4.4	0.00	1.0e+00	LRRC37A2 LRRC37A4P RABGAP1L
Arm fat mass (right)	3.28	3	2	4.4	0.00	1.0e+00	ANKS1A FAM108C1 UHRF1BP1
Myopia	3.28	2	0	0.0	0.00	1.0e+00	LRP1 LRRC37A2
Nervous feelings	3.26	2	2	4.4	0.00	1.0e+00	LRRC37A2 LRRC37A4P
Weight	3.25	5	2	4.4	-0.44	4.6e-01	ANKS1A CDK2AP1 FAM108C1 RABGAP1L UHRF1BP1
Qualifications: College or University degree	3.24	5	4	8.9	1.00	3.4e-04	CDK2AP1 LRRC37A2 LRRC37A4P RABGAP1L SDCCAG8
Coronary Artery Disease (CAD)	3.23	2	0	0.0	0.00	1.0e+00	ANKS1A UHRF1BP1
Qualifications: O levels/GCSEs or equivalent	3.23	1	1	2.2	0.00	1.0e+00	CDK2AP1
High blood pressure (siblings)	3.23	2	0	0.0	0.00	1.0e+00	CGREF1 FAM108C1
Arm fat mass (left)	3.23	3	2	4.4	0.00	1.0e+00	ANKS1A FAM108C1 UHRF1BP1
Primary Biliary Cirrhosis	3.22	2	0	0.0	0.00	1.0e+00	LRP1 LRRC37A2
Systolic Blood Pressure	3.22	8	3	6.7	-0.59	1.2e-01	CGREF1 FAM108C1 FHL5 LRRC37A2 LRRC37A4P MEF2D NRBP1 SDCCAG8
Qualifications: A levels/AS levels or equivalent	3.22	2	1	2.2	0.00	1.0e+00	CDK2AP1 SDCCAG8
Systolic blood pressure, automated reading	3.20	4	2	4.4	0.11	8.9e-01	FAM108C1 FHL5 LRRC37A2 LRRC37A4P
Arm fat percentage (left)	3.20	2	2	4.4	0.00	1.0e+00	ANKS1A UHRF1BP1
Hair/balding pattern: Pattern 2	3.19	2	1	2.2	0.00	1.0e+00	LRRC37A2 LRRC37A4P
Hand grip strength (left)	3.17	3	2	4.4	0.00	1.0e+00	ANKS1A LRRC37A2 LRRC37A4P
Lung FEV1/FVC ratio	3.16	6	1	2.2	0.58	2.2e-01	LRP1 LRRC37A2 LRRC37A4P MEF2D TARS2 TMEM194A
Arm fat percentage (right)	3.15	2	2	4.4	0.00	1.0e+00	ANKS1A UHRF1BP1
Hearing difficulty/problems with background noise	3.13	2	0	0.0	0.00	1.0e+00	LRRC37A2 LRRC37A4P
Taking other prescription medications	3.11	1	0	0.0	0.00	1.0e+00	UHRF1BP1
Allergy	3.09	3	2	4.4	0.00	1.0e+00	CDK2AP1 LRP1 TMEM194A
Medication: Amlodipine	3.08	1	0	0.0	0.00	1.0e+00	FAM108C1
Tense / 'highly strung'	3.05	1	1	2.2	0.00	1.0e+00	RABGAP1L
Bipolar Disorder or Schizophrenia	3.04	2	2	4.4	0.00	1.0e+00	CDK2AP1 U91328.21
Multivitamins +/- minerals	3.00	2	0	0.0	0.00	1.0e+00	LRP1 TMEM194A
Handedness (chirality/laterality): Left-handed	2.99	1	1	2.2	0.00	1.0e+00	LRRC37A2
Loneliness, isolation	2.99	1	0	0.0	0.00	1.0e+00	LRRC37A2
Schizophrenia (2014)	2.90	4	1	2.2	-0.73	2.7e-01	CDK2AP1 LRRC37A2 NRBP1 SDCCAG8
Exposure to tobacco smoke outside home	2.90	2	0	0.0	0.00	1.0e+00	LRRC37A4P SDCCAG8
Qualifications: None of the above	2.89	1	1	2.2	0.00	1.0e+00	CDK2AP1
Frequency of depressed mood in last 2 weeks	2.88	1	0	0.0	0.00	1.0e+00	LRRC37A2
Allergy or Eczema	2.87	3	1	2.2	0.00	1.0e+00	CDK2AP1 LRP1 TMEM194A
Supplements: Fish oil (including cod liver oil)	2.87	2	0	0.0	0.00	1.0e+00	KLF7 LRP1
Guilty feelings	2.81	2	0	0.0	0.00	1.0e+00	LRRC37A2 LRRC37A4P
Hand grip strength (right)	2.80	3	1	2.2	0.00	1.0e+00	LRP1 LRRC37A2 LRRC37A4P
Waist circumference	2.79	3	2	4.4	0.00	1.0e+00	ANKS1A FAM108C1 UHRF1BP1
Irritability	2.79	2	1	2.2	0.00	1.0e+00	LRRC37A2 LRRC37A4P
Emphysema/chronic bronchitis	2.77	1	0	0.0	0.00	1.0e+00	LRRC37A4P
Frequency of tiredness / lethargy in last 2 weeks	2.76	1	0	0.0	0.00	1.0e+00	KLF7
Medication for cholesterol, blood pressure or diabetes	2.76	1	0	0.0	0.00	1.0e+00	FAM108C1
Leg predicted mass (right)	2.74	5	3	6.7	-0.10	8.7e-01	CDK2AP1 CGREF1 FAM108C1 KLF7 UHRF1BP1
Leg predicted mass (left)	2.73	4	3	6.7	-0.22	7.8e-01	CDK2AP1 CGREF1 FAM108C1 UHRF1BP1
Leg fat-free mass (left)	2.72	4	3	6.7	-0.22	7.8e-01	CDK2AP1 CGREF1 FAM108C1 UHRF1BP1
Leg fat-free mass (right)	2.72	4	3	6.7	-0.20	8.0e-01	CDK2AP1 FAM108C1 KLF7 UHRF1BP1
Time employed in main current job	2.70	1	0	0.0	0.00	1.0e+00	LRRC37A2
Medication: Levothyroxine sodium	2.69	2	1	2.2	0.00	1.0e+00	ANKS1A UHRF1BP1
Basal metabolic rate	2.69	5	3	6.7	-0.09	8.9e-01	CDK2AP1 CGREF1 FAM108C1 RABGAP1L UHRF1BP1
Comparative height size at age 10	2.68	6	4	8.9	0.21	6.9e-01	CDK2AP1 CGREF1 FAM108C1 LRRC37A2 LRRC37A4P U91328.21
Supplements: Vitamin C	2.68	1	0	0.0	0.00	1.0e+00	LRRC37A2
Number of live births	2.65	2	0	0.0	0.00	1.0e+00	LRRC37A2 LRRC37A4P
Mineral and other dietary supplements	2.65	1	0	0.0	0.00	1.0e+00	LRP1
Had menopause	2.61	2	0	0.0	0.00	1.0e+00	CDK2AP1 NRBP1
Medication: Blood pressure	2.61	1	1	2.2	0.00	1.0e+00	FAM108C1
Long-standing illness, disability or infirmity	2.59	2	0	0.0	0.00	1.0e+00	KLF7 UHRF1BP1
Arm predicted mass (left)	2.57	5	3	6.7	-0.05	9.4e-01	CDK2AP1 CGREF1 FAM108C1 RABGAP1L UHRF1BP1
Pain type(s) experienced in last month: Hip pain	2.54	1	0	0.0	0.00	1.0e+00	TARS2
Whole body fat-free mass	2.53	5	3	6.7	-0.01	9.9e-01	CDK2AP1 CGREF1 FAM108C1 KLF7 UHRF1BP1
Qualifications: nursing, teaching	2.53	1	1	2.2	0.00	1.0e+00	CDK2AP1
Whole body water mass	2.53	5	3	6.7	-0.01	9.9e-01	CDK2AP1 CGREF1 FAM108C1 KLF7 UHRF1BP1
Major Depression (MDD)	2.51	1	0	0.0	0.00	1.0e+00	KLF7
Fluid intelligence score	2.50	2	0	0.0	0.00	1.0e+00	CDK2AP1 U91328.21
Osteoarthritis (self-reported)	2.50	1	0	0.0	0.00	1.0e+00	TARS2
Arm fat-free mass (left)	2.49	5	3	6.7	-0.04	9.5e-01	CDK2AP1 CGREF1 FAM108C1 RABGAP1L UHRF1BP1
High blood pressure (mother)	2.46	1	0	0.0	0.00	1.0e+00	CGREF1
Medication: Laxatives (e.g. Dulcolax, Senokot)	2.44	1	0	0.0	0.00	1.0e+00	CGREF1
Trunk predicted mass	2.41	6	4	8.9	-0.04	9.5e-01	CDK2AP1 CGREF1 FAM108C1 LRP1 RABGAP1L UHRF1BP1
Hayfever/allergic rhinitis (self-reported)	2.40	1	0	0.0	0.00	1.0e+00	LRP1
Trunk fat-free mass	2.40	6	4	8.9	-0.03	9.5e-01	CDK2AP1 CGREF1 FAM108C1 LRP1 RABGAP1L UHRF1BP1
Medication: Bendroflumethiazide	2.39	1	0	0.0	0.00	1.0e+00	FAM108C1
Arm predicted mass (right)	2.38	4	3	6.7	-0.16	8.4e-01	CDK2AP1 CGREF1 FAM108C1 UHRF1BP1
Arm fat-free mass (right)	2.35	4	3	6.7	-0.13	8.7e-01	CDK2AP1 CGREF1 FAM108C1 UHRF1BP1
Intelligence (Savage-Jansen 2018)	2.31	3	1	2.2	0.00	1.0e+00	CDK2AP1 LRRC37A2 RABGAP1L
Height	2.31	9	8	17.8	0.41	2.8e-01	ANKS1A CDK2AP1 CGREF1 LRP1 LRRC37A2 LRRC37A4P MEF2D NRBP1 UHRF1BP1
Number of full brothers	2.31	1	0	0.0	0.00	1.0e+00	LRRC37A2
Worrier / anxious feelings	2.29	2	1	2.2	0.00	1.0e+00	LRRC37A2 LRRC37A4P
Medication: Cholesterol lowering	2.27	2	0	0.0	0.00	1.0e+00	CGREF1 MEF2D
Verbal and Numeric Reasoning (VNR)	2.26	2	1	2.2	0.00	1.0e+00	CDK2AP1 U91328.21
Hayfever, allergic rhinitis or eczema	2.25	3	1	2.2	0.00	1.0e+00	CDK2AP1 LRP1 TMEM194A
Comparative body size at age 10	2.23	3	1	2.2	0.00	1.0e+00	TARS2 U91328.21 UHRF1BP1
Breast Cancer	2.20	2	1	2.2	0.00	1.0e+00	LRRC37A2 LRRC37A4P
Supplements: Glucosamine	2.18	1	0	0.0	0.00	1.0e+00	TARS2
Mouth/teeth dental problems	2.18	1	0	0.0	0.00	1.0e+00	SDCCAG8
Ever had prostate specific antigen (PSA) test	2.16	1	0	0.0	0.00	1.0e+00	U91328.21
Commuting to job workplace: Cycle	2.13	1	0	0.0	0.00	1.0e+00	UHRF1BP1
Illnesses of father: Heart disease	2.11	1	0	0.0	0.00	1.0e+00	LRRC37A2
Impedance of whole body	2.11	5	2	4.4	0.34	5.8e-01	CGREF1 FAM108C1 LRRC37A2 TARS2 UHRF1BP1
Pulse rate, automated reading	2.09	3	2	4.4	0.00	1.0e+00	MEF2D RABGAP1L UHRF1BP1
Alcohol usually taken with meals	2.08	1	0	0.0	0.00	1.0e+00	RABGAP1L
Ever unenthusiastic/disinterested for a whole week	2.06	1	0	0.0	0.00	1.0e+00	LRRC37A2
Standing height	2.06	8	4	8.9	0.39	3.4e-01	ANKS1A CDK2AP1 CGREF1 KLF7 LRP1 LRRC37A2 LRRC37A4P U91328.21
Average weekly red wine intake	2.06	1	0	0.0	0.00	1.0e+00	CDK2AP1
Chronotype (morning person)	2.05	1	1	2.2	0.00	1.0e+00	TARS2
Seen doctor (GP) for nerves, anxiety, tension or depression	2.05	1	0	0.0	0.00	1.0e+00	U91328.21
Medication: Atorvastatin	2.04	1	0	0.0	0.00	1.0e+00	CGREF1
Blood White Count	2.03	7	2	4.4	-0.70	7.9e-02	CGREF1 LRRC37A2 LRRC37A4P MEF2D NRBP1 TARS2 UHRF1BP1
Medication: Allopurinol	2.03	1	0	0.0	0.00	1.0e+00	CGREF1
Fractured/broken bones in last 5 years	2.02	1	0	0.0	0.00	1.0e+00	LRRC37A2
Impedance of arm (left)	2.01	4	1	2.2	0.68	3.2e-01	CGREF1 FAM108C1 LRRC37A2 UHRF1BP1
Heel T-Score	2.00	4	3	6.7	0.25	7.5e-01	CDK2AP1 LRRC37A2 LRRC37A4P MEF2D
Lupus	1.97	1	0	0.0	0.00	1.0e+00	UHRF1BP1
Ever depressed for a whole week	1.97	1	0	0.0	0.00	1.0e+00	LRRC37A2
Impedance of leg (right)	1.92	4	2	4.4	0.19	8.1e-01	FAM108C1 KLF7 TARS2 UHRF1BP1
Impedance of leg (left)	1.89	5	1	2.2	0.46	4.4e-01	CDK2AP1 FAM108C1 LRRC37A2 TARS2 UHRF1BP1
Worry too long after embarrassment	1.85	1	0	0.0	0.00	1.0e+00	LRRC37A2
Reaction Time	1.81	1	0	0.0	0.00	1.0e+00	TARS2
Risk taking	1.81	2	0	0.0	0.00	1.0e+00	SDCCAG8 U91328.21
Impedance of arm (right)	1.80	4	1	2.2	0.70	3.0e-01	CGREF1 FAM108C1 LRRC37A2 UHRF1BP1
Breastfed as a baby	1.76	1	0	0.0	0.00	1.0e+00	CDK2AP1
Exposure to tobacco smoke at home	1.66	1	0	0.0	0.00	1.0e+00	UHRF1BP1
Hypothyroidism/myxoedema (self-reported)	1.65	1	0	0.0	0.00	1.0e+00	UHRF1BP1
Mean time to correctly identify matches	1.62	1	0	0.0	0.00	1.0e+00	KLF7
Friendships satisfaction	1.59	1	0	0.0	0.00	1.0e+00	TARS2
Diverticular disease/diverticulitis (self-reported)	1.58	1	0	0.0	0.00	1.0e+00	LRRC37A2
Father's age at death	1.58	1	0	0.0	0.00	1.0e+00	CDK2AP1
HDL Cholesterol	1.57	1	0	0.0	0.00	1.0e+00	UHRF1BP1
Ever smoked	1.57	1	0	0.0	0.00	1.0e+00	CDK2AP1
Type 2 Diabetes (T2D) (2018)	1.56	1	0	0.0	0.00	1.0e+00	CDK2AP1
Unable to work because of sickness or disability	1.55	1	0	0.0	0.00	1.0e+00	UHRF1BP1
Hypothyroidism (self reported)	1.29	1	0	0.0	0.00	1.0e+00	UHRF1BP1
Hair Pigment	0.52	7	2	4.4	0.05	9.2e-01	CDK2AP1 CGREF1 LRP1 LRRC37A2 LRRC37A4P NRBP1 TMEM194A

Associations by panel

study	tissue	# hits	% hits/tests	avg chisq
GTEx	Small Intestine Terminal Ileum	3	0.651	2.1
GTEx	Uterus	6	1.058	2.0
GTEx	Adipose Visceral Omentum	5	0.246	1.9
GTEx	Artery Coronary	5	0.423	1.9
GTEx	Artery Tibial	10	0.266	1.9
GTEx	Brain Cerebellum	5	0.252	1.9
GTEx	Brain Cortex	4	0.386	1.9
GTEx	Brain Nucleus accumbens basal ganglia	4	0.462	1.9
GTEx	Brain Putamen basal ganglia	4	0.641	1.9
GTEx	Cells EBV-transformed lymphocytes	5	0.351	1.9
GTEx	Colon Transverse	5	0.242	1.9
GTEx	Liver	2	0.279	1.9
GTEx	Pancreas	5	0.306	1.9
GTEx	Prostate	3	0.359	1.9
GTEx	Skin Not Sun Exposed Suprapubic	5	0.203	1.9
GTEx	Stomach	6	0.413	1.9
GTEx	Vagina	4	0.630	1.9
GTEx	Adipose Subcutaneous	6	0.172	1.8
GTEx	Adrenal Gland	2	0.137	1.8
GTEx	Artery Aorta	6	0.202	1.8
GTEx	Brain Cerebellar Hemisphere	4	0.269	1.8
GTEx	Brain Frontal Cortex BA9	4	0.433	1.8
GTEx	Brain Hippocampus	3	0.573	1.8
GTEx	Breast Mammary Tissue	6	0.304	1.8
GTEx	Breast Mammary Tissue (Male)	6	0.503	1.8
GTEx	Breast Mammary Tissue (Female)	6	0.365	1.8
GTEx	Cells Transformed fibroblasts	6	0.143	1.8
GTEx	Colon Sigmoid	6	0.410	1.8
GTEx	Esophagus Gastroesophageal Junction	6	0.415	1.8
GTEx	Esophagus Mucosa	8	0.241	1.8
GTEx	Esophagus Muscularis	9	0.278	1.8
GTEx	Heart Left Ventricle	5	0.327	1.8
GTEx	Lung	9	0.313	1.8
GTEx	Muscle Skeletal	6	0.208	1.8
GTEx	Ovary	4	0.441	1.8
GTEx	Pituitary	3	0.269	1.8
GTEx	Skin Sun Exposed Lower leg	10	0.275	1.8
GTEx	Spleen	2	0.142	1.8
GTEx	Testis	7	0.222	1.8
The Cancer Genome Atlas	Esophageal Carcinoma	1	0.146	1.8
The Cancer Genome Atlas	Uterine Corpus Endometrial Carcinoma	0	0.000	1.8
GTEx	Brain Caudate basal ganglia	4	0.435	1.7
GTEx	Brain Hypothalamus	3	0.508	1.7
GTEx	Heart Atrial Appendage	5	0.317	1.7
GTEx	Nerve Tibial	8	0.185	1.7
GTEx	Thyroid	7	0.175	1.7
GTEx	Whole Blood	5	0.251	1.7
CommonMind	Brain Pre-frontal Cortex	4	0.074	1.7
The Cancer Genome Atlas	Bladder Urothelial Carcinoma	1	0.060	1.7
The Cancer Genome Atlas	Head and Neck Squamous Cell Carcinoma	1	0.037	1.7
The Cancer Genome Atlas	Liver Hepatocellular Carcinoma	1	0.090	1.7
The Cancer Genome Atlas	Lung Adenocarcinoma	3	0.102	1.7
The Cancer Genome Atlas	Lung Squamous Cell Carcinoma	1	0.040	1.7
The Cancer Genome Atlas	Pancreatic Adenocarcinoma	3	0.181	1.7
The Cancer Genome Atlas	Soft Tissue Sarcoma	0	0.000	1.7
The Cancer Genome Atlas	Skin Cutaneous Melanoma	0	0.000	1.7
METSIM	Adipose	3	0.065	1.6
NTR	Blood	4	0.167	1.6
ROSMAP	Brain Pre-frontal Cortex	1	0.023	1.6
YFS	Blood	0	0.000	1.6
The Cancer Genome Atlas	Breast Invasive Carcinoma	0	0.000	1.6
The Cancer Genome Atlas	Cervical Squamous Cell Carcinoma	0	0.000	1.6
The Cancer Genome Atlas	Colon Adenocarcinoma	0	0.000	1.6
The Cancer Genome Atlas	Glioblastoma Multiforme	0	0.000	1.6
The Cancer Genome Atlas	Kidney Renal Clear Cell Carcinoma	2	0.049	1.6
The Cancer Genome Atlas	Brain Lower Grade Glioma	0	0.000	1.6
The Cancer Genome Atlas	Ovarian Serous Cystadenocarcinoma	0	0.000	1.6
The Cancer Genome Atlas	Pheochromocytoma and Paraganglioma	0	0.000	1.6
The Cancer Genome Atlas	Prostate Adenocarcinoma	1	0.022	1.6
The Cancer Genome Atlas	Rectum Adenocarcinoma	1	0.145	1.6
The Cancer Genome Atlas	Stomach Adenocarcinoma	0	0.000	1.6
The Cancer Genome Atlas	Testicular Germ Cell Tumors	0	0.000	1.6
The Cancer Genome Atlas	Thyroid Carcinoma	4	0.078	1.6
The Cancer Genome Atlas	Kidney Renal Papillary Cell Carcinoma	1	0.049	1.5